{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:50:23Z","timestamp":1790297423043,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Medical Scientific Research Foundation of Guangdong Province","award":["B2013006"],"award-info":[{"award-number":["B2013006"]}]},{"name":"Science and Technology Planning Project from Guangdong Province","award":["2014A020212587"],"award-info":[{"award-number":["2014A020212587"]}]},{"name":"Science and Technology Special Foundation of Guangdong General Hospital"},{"name":"Science and Technology Program of Guangzhou","award":["201804010331"],"award-info":[{"award-number":["201804010331"]}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2018A030313989"],"award-info":[{"award-number":["2018A030313989"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.euroneuro.2018.12.010","type":"journal-article","created":{"date-parts":[[2018,12,27]],"date-time":"2018-12-27T17:42:20Z","timestamp":1545932540000},"page":"397-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study"],"prefix":"10.1016","volume":"29","author":[{"given":"Huirong","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangquan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2018.12.010_bib0001","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5\u00ae)","year":"2013"},{"issue":"9","key":"10.1016\/j.euroneuro.2018.12.010_bib0002","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11920-016-0720-3","article-title":"Cognitive dysfunction in obsessive-compulsive disorder","volume":"18","author":"Benzina","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"issue":"7","key":"10.1016\/j.euroneuro.2018.12.010_bib0003","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/sj.mp.4001823","article-title":"A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.12.010_bib0004","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/070674371205700206","article-title":"Prevalence of prescribed attention-deficit hyperactivity disorder medications and diagnosis among Canadian preschoolers and school-age children: 1994\u20132007","volume":"57","author":"Brault","year":"2012","journal-title":"Can. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2018.12.010_bib0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s12402-014-0146-x","article-title":"The neurobiological link between OCD and ADHD","volume":"6","author":"Brem","year":"2014","journal-title":"Atten. Defic. Hyperact. Disord."},{"issue":"2","key":"10.1016\/j.euroneuro.2018.12.010_bib0006","first-page":"179","article-title":"Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: a case report and review literature","volume":"18","author":"Buhagiar","year":"2007","journal-title":"Turk. Psikiyatri. Derg."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.12.010_bib0007","first-page":"287","article-title":"SAFTEE: data system for side effect assessment scale","volume":"22","author":"Clyde","year":"1986","journal-title":"Psychopharmacol. Bull."},{"issue":"11","key":"10.1016\/j.euroneuro.2018.12.010_bib0008","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.euroneuro.2013.05.012","article-title":"Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder","volume":"23","author":"Denys","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"11","key":"10.1016\/j.euroneuro.2018.12.010_bib0009","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch. Gen. Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2018.12.010_bib0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/npp.2009.128","article-title":"Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for OCD","volume":"35","author":"Greenberg","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.euroneuro.2018.12.010_bib0011","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1177\/0269881109348172","article-title":"Depression, anxiety and obsessive-compulsive symptoms and quality of life in children with attention-deficit hyperactivity disorder (ADHD) during three-month methylphenidate treatment","volume":"24","author":"Gurkan","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.12.010_bib0012","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"key":"10.1016\/j.euroneuro.2018.12.010_bib0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2018.12.010_bib0014","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int. J. Methods Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.euroneuro.2018.12.010_bib0015","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/1039856216671664","article-title":"Methylphenidate in the treatment of an adolescent female with obsessive-compulsive disorder and attention deficit hyperactivity disorder: a case report","volume":"25","author":"King","year":"2017","journal-title":"Australas. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.12.010_bib0016","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1586\/ern.09.148","article-title":"Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder","volume":"10","author":"Koo","year":"2010","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.euroneuro.2018.12.010_bib0017","article-title":"Promising treatments for obsessive-compulsive disorder: a call for additional research","author":"Koran","year":"2017","journal-title":"Curr. Med. Chem."},{"issue":"11","key":"10.1016\/j.euroneuro.2018.12.010_bib0018","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.4088\/JCP.08m04605","article-title":"Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"70","author":"Koran","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"2","key":"10.1016\/j.euroneuro.2018.12.010_bib0019","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/01.JGP.0000192503.10692.9f","article-title":"Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial","volume":"14","author":"Lavretsky","year":"2006","journal-title":"Am. J. Geriatr Psychiatry"},{"issue":"6","key":"10.1016\/j.euroneuro.2018.12.010_bib0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1176\/appi.ajp.2014.14070889","article-title":"Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial","volume":"172","author":"Lavretsky","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2018.12.010_bib0021","article-title":"Long-term efficacy of methylphenidate immediate-release for the treatment of childhood ADHD: a systematic review and meta-analysis","author":"Maia","year":"2014","journal-title":"J. Atten. Disord."},{"issue":"8","key":"10.1016\/j.euroneuro.2018.12.010_bib0022","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/pcn.12195","article-title":"Neurobiological model of obsessive-compulsive disorder: evidence from recent neuropsychological and neuroimaging findings","volume":"68","author":"Nakao","year":"2014","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.euroneuro.2018.12.010_bib0023","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrn3746","article-title":"Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective","volume":"15","author":"Pauls","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.12.010_bib0024","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.neuroimage.2008.04.233","article-title":"In vivo PET study of 5HT(2A) serotonin and D(2) dopamine dysfunction in drug-naive obsessive-compulsive disorder","volume":"42","author":"Perani","year":"2008","journal-title":"Neuroimage"},{"issue":"3","key":"10.1016\/j.euroneuro.2018.12.010_bib0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/JCP.0b013e318290115e","article-title":"Does extended release methylphenidate help adults with hoarding disorder? A case series","volume":"33","author":"Rodriguez","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.12.010_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.euroneuro.2018.12.010_bib0027","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0166-4328(01)00435-1","article-title":"Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis","volume":"130","author":"Seeman","year":"2002","journal-title":"Behav. Brain Res."},{"issue":"6","key":"10.1016\/j.euroneuro.2018.12.010_bib0028","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1017\/S146114571200154X","article-title":"Evaluation of animal models of obsessive-compulsive disorder: correlation with phasic dopamine neuron activity","volume":"16","author":"Sesia","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2018.12.010_bib0029","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD)","author":"Soomro","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.euroneuro.2018.12.010_bib0030","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1375\/twin.8.5.450","article-title":"Twin studies on obsessive-compulsive disorder: a review","volume":"8","author":"van Grootheest","year":"2005","journal-title":"Twin Res. Hum. Genet."},{"key":"10.1016\/j.euroneuro.2018.12.010_bib0031","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","article-title":"Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"14","author":"Veale","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.euroneuro.2018.12.010_bib0032","doi-asserted-by":"crossref","first-page":"PL7","DOI":"10.1016\/S0024-3205(99)00225-8","article-title":"Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain","volume":"65","author":"Volkow","year":"1999","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.euroneuro.2018.12.010_bib0033","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/syn.10038","article-title":"Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications","volume":"43","author":"Volkow","year":"2002","journal-title":"Synapse"},{"issue":"3","key":"10.1016\/j.euroneuro.2018.12.010_bib0034","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/syn.10075","article-title":"\"Nonhedonic\" food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect","volume":"44","author":"Volkow","year":"2002","journal-title":"Synapse"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18320005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X18320005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T01:42:21Z","timestamp":1565228541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X18320005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0924977X18320005"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.12.010","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2018.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}